MolNFT v1 · #118320 · protein
Crystal structure of C-met in complex with naphthyridinone inhibitor 5
5EYC · Hepatocyte growth factor receptor: “Crystal structure of C-met in complex with naphthyridinone inhibitor 5”. X-ray diffraction, 1 ligand (5SZ), 3 pockets (best druggability 0.64). MolNFT v1 #118320 on GenesisL1: 3D structure…
- PDB
- 5EYC
- Type
- protein
- Length
- 288 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Hepatocyte growth factor receptor
- EC
- 2.7.10.1
- UniProt
- P08581
- Ligands
- 5SZ
- Pockets
- 3 · best druggability 0.64
Structure
x-ray diffraction · 1 distinct chain · 43% helix, 16% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Hepatocyte growth factor receptor (EC 2.7.10.1) | protein | 288 | 43% helix, 16% strand | P08581 |
Ligands and binding sites
- 5SZ · 6-[(1~{R})-1-[8-fluoranyl-6-(3-methyl-1,2-oxazol-5-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-1,6-naphthyridin-5-one · ligand · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
3 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 222 | 0.64 | 0.83 | 25 | 5SZ |
| 2 | 101 | 0.38 | 0.75 | 12 | empty |
| 3 | 96 | 0.35 | 0.74 | 19 | empty |
Compared structures
- 5EYC · Crystal structure of c-Met in complex with naphthyridi inhibitor 5 · the same entry in another collection · chain A against A, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt P08581
- Elsewhere: RCSB PDB 5EYC · PDBe 5EYC · UniProt P08581
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.